Aclaris Therapeutics (ACRS) Short-term Investments (2014 - 2026)

Aclaris Therapeutics' Short-term Investments history runs 13 years deep, the most recent figure standing at $76.8 million for Q1 2026.

• On a quarterly basis, Short-term Investments rose 2.4% year-over-year to $76.8 million in Q1 2026; TTM through Mar 2026 was $76.8 million, a 2.4% increase from a year earlier, with the FY2025 full-year figure at $70.8 million, down 20.48% from the prior year.
• Short-term Investments climbed to $76.8 million in Q1 2026 per ACRS's latest filing, from $70.8 million in the prior quarter.
• Across five years, Short-term Investments topped out at $186.4 million in Q3 2022 and bottomed at $64.0 million in Q3 2023.
• The 5-year median for Short-term Investments is $88.3 million (2024), against an average of $103.4 million.
• Across the five-year window, Short-term Investments surged 54.02% in 2022 and slumped 65.66% in 2023, its largest moves.
• Year by year, Short-term Investments stood at $172.3 million in 2022, then slumped by 54.02% to $79.2 million in 2023, then rose by 12.36% to $89.0 million in 2024, then declined by 20.48% to $70.8 million in 2025, then grew by 8.43% to $76.8 million in 2026.
• Per Business Quant, the three latest ACRS Short-term Investments figures stand at $76.8 million (Q1 2026), $70.8 million (Q4 2025), and $70.7 million (Q3 2025).